Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 18:37:100993.
doi: 10.1016/j.ymgmr.2023.100993. eCollection 2023 Dec.

A new multiplex analysis of glucosylsphingosine and globotriaosylsphingosine in dried blood spots by tandem mass spectrometry

Amber Van Baelen  1   2   3 , Laurence Roosens  4 , Sylvie Devos  4 , Stijn Verhulst  2   3 , François Eyskens  1   2   3
Affiliations

A new multiplex analysis of glucosylsphingosine and globotriaosylsphingosine in dried blood spots by tandem mass spectrometry

Amber Van Baelen et al. Mol Genet Metab Rep. .

Abstract

Background: Gaucher's and Fabry's disease are two of the most common treatable lysosomal storage diseases, and have a wide spectrum of clinical symptoms. Early detection is important, because timely initiation of treatments can improve the disease status and prevent complications. However disease manifestations develop in childhood, diagnosis is delayed until adulthood partly due to the limitations of the currently used diagnostic pathway. The aim of this research is to develop and validate a multiplex assay and defining reference ranges, which do not exist at this moment, to improve and facilitate the entire diagnostic work up and enable treatment in an earlier stage of disease.

Methods and findings: Biomarkers glucosylsphingosine (GlcSph) and globotriaosylsphingosine (Lyso-Gb3) were detected and quantified using LC-MS/MS on dried blood spots. We developed an improved and new extraction method that allowed to measure GlcSph and Lyso-Gb3 in a multiplex analytical platform. After validation of the method, samples of 1480 individuals with normal enzymatic activity were collected to determine age and gender-related reference ranges.Our combination method showed a good linearity, precision, accuracy and limit of quantification with lack of carry-over following the specific international CLSI guidelines. The suggested protocol is robust, efficient, sensitive, specific, comprehensive and relatively cheap in order to accelerate the diagnostic process for both lysosomal storage diseases. The samples, with normal enzymatic activity, defined statistical relevant and clinical correct reference ranges for each specific age group by gender.

Conclusion: We report a multiplex LC-MS/MS method and relevant reference ranges that are appropriate for the targeted screening, diagnosis and follow-up of Fabry and Gaucher disease.

Keywords: Biomarker; Dried blood spots; Globotriaosylsphingosine; Glucosylsphingosine; Lysosomal storage diseases; Reference ranges; Tandem mass spectrometry.

PubMed Disclaimer

Conflict of interest statement

The author François Eyskens is the president of Metabolics.be and a member of the MetabERN Medical Executive Committee. Additionally he attended advisory boards and received speaking fees and travel grants from Takeda, Sanofi, Recordati, Protalix, Amicus, Acthelion, Alexion, Chiesi and Ultragenyx. The other authors have nothing to disclose.

Figures

Fig. 1
Fig. 1
Linearity of the calibration curve. Representation of the linearity based on the 7 standard values for each biomarker. Analyzation by comparing the spiked concentrations with the measured concentrations. Concentration units are expressed in ng/mL (or 10−6 g/L). (A) Bland-Altman curve for GlcSph. (B) Bland-Altman curve for Lyso-Gb3. (C) Passing Bablok Regression and the Spearman's test for GlcSph. (D) Passing Bablok Regression and the Spearman's test for Lyso-Gb3.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Stirnemann J., Belmatoug N., Camou F., Serratrice C., Froissart R., Caillaud C., et al. A review of gaucher disease pathophysiology, clinical presentation and treatments. Int. J. Mol. Sci. 2017;18:1–30. doi: 10.3390/ijms18020441. - DOI - PMC - PubMed
    1. Beutler E., Grabowski G.A. In: The Metabolic and Molecular Bases of Inherited Disease. 8th edition. Scriver C., Beaudet A.L., Sly W.S., Valle D., editors. vol 3;16. McGraw-Hill; New York: 2001. Gaucher disease; pp. 3635–3668. - DOI
    1. Desnick R.J., Ioannou Y.A., Eng C.M. In: The Metabolic and Molecular Bases of Inherited Disease. 8th edition. Scriver C., Beaudet A.L., Sly W.S., Valle D., editors. vol3;16. McGraw-Hill; New York: 2001. α-Falactosidase deficiency: Fabry disease; pp. 3733–3774. - DOI
    1. Wenger D.A., Coppola S., Liu S.L. Lysosomal storage disorders: diagnostic dilemmas and prospects for therapy. Genet. Med. 2002;4:412–419. doi: 10.1097/00125817-200211000-00003. - DOI - PubMed
    1. Dinur T., Bauer P., Beetz C., Kramp G., Cozma C., Ionu M., et al. Gaucher disease diagnosis using lyso-Gb1 on dry blood spot samples: time to change the paradigm. Int. J. Mol. Sci. 2022;23:1–11. doi: 10.3390/ijms23031627. - DOI - PMC - PubMed

LinkOut - more resources